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ABSTRACT
In this paper we outline the current data capture systems for
human immunodeficiency virus (HIV) and sexually trans-
mitted infection (STI) surveillance used by Public Health
England (PHE), and how these will be affected by the in-
troduction of novel testing platforms and changing patient
pathways. We outline the Chlamydia Online Clinical Care
Pathway (COCCP), developed as part of the Electronic Self-
Testing for Sexually Transmitted Infections (eSTI2) Consor-
tium, which ensures that surveillance data continue to be
routinely collected and transmitted to PHE. We conclude
that both novel diagnostic testing platforms and established
data capture systems must be adaptable to ensure continued
robust public health surveillance.
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1. INTRODUCTION
Public Health England (PHE) collects comprehensive elec-
tronic surveillance data from a variety of sources. In the
human immunodeficiency virus (HIV) and sexually trans-
mitted infection (STI) Department, these include data on
numbers of STI tests, diagnoses, and associated epidemio-
logical information from sexual health services (GUMCAD),
data on all chlamydia tests and outcomes from laboratories
(CTAD), data on antimicrobial resistance patterns for gon-
orrhea from linked microbiological and clinical data (GRASP),
data on HIV and AIDS reporting covering all service providers
of English HIV outpatient services (HARS), and data on
the number of patients who recently acquired HIV infec-
tion at the time of diagnosis (RITA). Consequently, England
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has timely, comprehensive and sophisticated HIV and STI
surveillance systems, which compare favorably with those in
other western industrialized countries.
Although internet requesting of STI sampling kits for home
use is widely available in the UK, users return their samples
to the laboratory for testing, and ongoing management fol-
lows traditional care pathways. Therefore, there is minimal
impact on data acquisition for surveillance purposes. Simi-
larly for HIV, pilots of an HIV self-sampling service accessed
through the internet have proved very successful in the UK
and this is now already considered part of standard of care.
New diagnostic test platforms, such as rapid tests and Point-
of-Care (PoC) technologies, have the potential to be used in
novel settings such as people’s homes (home or self-sampling/-
self-testing). An HIV self-test was licensed in early 2014, and
although there is as yet no CE-marked kit available on the
market, there are both anticipated impacts on surveillance
because of the difficulties in monitoring those who are being
tested, as well as the challenge of ensuring positive results
are linked into care services for confirmation, treatment and
care. Data from England’s National Chlamydia Screening
Programme (NCSP) show that 7% of chlamydia testing is
internet-based, with high positivity of 11%, demonstrating
the importance of being able to capture surveillance-related
data from those being tested with new diagnostic technolo-
gies, for the meaningful assessment of testing patterns and
trends in STI rates.
2. CHANGING PATIENT PATHWAYS
Surveillance systems and their data sources will therefore
need to adapt and be ready as these tests become cheaper,
more accurate, and more widely available. This is particu-
larly true if these tests become de-coupled from traditional
care pathways. For example, the electronic self-testing for
sexually transmitted infections (eSTI2) consortium aims to
reduce the high impact of infectious diseases by linking the
capacity to develop and implement simple to use, rapid, ac-
curate tests for multiple infections which are affordable, reli-
able and can be mobile-phone networked, to on-line clinical
care pathways (http://www.esti2.org.uk/). Figure 1 depicts
the current general patient pathways for sample collection,
testing, and data transmission for surveillance purposes of
STIs in England.
Figure 1: Patient pathways involving established
and novel sample collection, testing and data cap-
ture mechanisms.
Self-sampling can be done either as part of a health care
worker (HCW) consultation, or without HCW involvement.
Samples from both these methods can be sent for established
testing methods, at the clinic or direct to laboratories, where
data are routinely transmitted to PHE (STI clinics to GUM-
CAD, laboratories to CTAD). However, a self-collected sam-
ple without a HCW can also be tested using novel rapid or
PoC tests. These could become available through routine
services, or they could be privately bought tests. Private
market testing and diagnosis data are already not captured
by existing surveillance systems, but the advent of novel
sampling and testing methods could increase the size of the
private market. Rapid and PoC testing, and increase in pri-
vate market tests, will result in loss of data capture by PHE,
unless they can be coupled with a new data capture system,
such as an online clinical care pathway.
As part of eSTI2, the Chlamydia Online Clinical Care Path-
way (COCCP) has been developed. This eClinical care path-
way focuses on the UK’s most commonly diagnosed STI
(Chlamydia trachomatis). The pathway enables people with
genital chlamydia to receive their test result online, obtain
information about the infection, complete a clinical consul-
tation, and progress to receive a remote prescription of an-
tibiotic treatment, within “eSexual Health clinics”, embed-
ded within England’s National Health Service (NHS) sexual
health services. An important part of the development of
the eClinical Care Pathway Framework was ensuring that
surveillance data continued to be routinely collected and
transmitted to PHE. The COCCP was specifically designed
to capture all data items routinely collected in traditional
consultations for public health surveillance purposes and for
the data to be captured through established mechanisms
(GUMCAD for STI clinic data, and CTAD for laborato-
ries). The system was also designed to be interoperable so
that in the future, surveillance data could be fed directly
from the COCCP to PHE and that data could be captured
through information input via the internet, or into a mobile
phone or other hand-held device by the PoC test user. How-
ever, the success of such pathways will be dependent on the
willingness of users to provide their data, particularly test-
negative patients who would have no contact with services
once they received their test result, and for whom surveil-
lance data would need to be collected prior to receiving their
test result.
Although there may be a risk that these new care path-
ways would cater for the “worried-well”, they may also in-
crease testing in high risk populations by removing barriers
to testing in current traditional and outreach settings. The
advent of new technologies may also make data harder to
interpret, as trends observed may result from changing pop-
ulation testing profiles as opposed to intrinsic changes in
infection rates. Interpretation is further complicated by the
need for identification and removal of duplicates (individu-
als tested more than once, for example, in community and
clinical settings) once the data have been transmitted to
PHE. Although deduplication is already an issue in existing
surveillance systems, home sampling and testing will likely
add to this problem as individuals test at home and then
attend a more traditional setting for confirmatory testing.
Identifying when confirmatory testing is taking place would
have the additional advantage of verifying the initial PoC
test result. Further, having a CE-mark does not guaran-
tee that the test has high sensitivity or specificity. If there
are no robust controls of tests available to buy for home- or
self-testing, or pathways to confirm test result, patients may
receive inaccurate diagnoses and management.
3. CONCLUSIONS
In conclusion, a critical concern for any established surveil-
lance system currently dependent on data obtained from
public sources, is the loss of data as individuals no longer
engage with established services and are instead tested and
managed remotely. If online self-testing, such as that de-
scribed here, was commissioned by a public body, such as
the National Health Service, public health monitoring would
need to be part of the pathway. Mechanisms of data capture
for surveillance purposes could also be incorporated into pri-
vate market tests. There is flexibility in the existing surveil-
lance structure to adapt to, and accommodate, novel tests
and patient management systems. Engaging with those re-
sponsible for established STI/HIV surveillance would need
to take place early on in the development of remote care
pathways.
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